Exploring the Validity of the Short Version of the Problem Behaviours Assessment (PBA-s) for Huntington’s disease: A Rasch Analysis-Reference-Cited by-同舟云学术

Exploring the Validity of the Short Version of the Problem Behaviours Assessment (PBA-s) for Huntington’s disease: A Rasch Analysis

Published:2015-12-27 Issue:4 Volume:4 Page:347-369
ISSN:1879-6397
Container-title:Journal of Huntington's Disease
language:
Short-container-title:JHD

Author:

McNally George¹,Rickards Hugh²,Horton Mike³,Craufurd David⁴

Affiliation:

1. College of Medical and Dental Sciences, University of Birmingham, UK

2. Department of Neuropsychiatry, The Barberry, Birmingham, UK

3. Academic Department of Rehabilitation Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

4. Faculty of Medicine and Human Sciences, Institute of Human Development, University of Manchester and Manchester Academic Health Science Centre, Manchester, UK

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference43 articles.

1. Behavioral changes in Huntington Disease;Craufurd;Neuropsychiatry Neuropsychol Behav Neurol,2001

2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–83.

3. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis;Pringsheim;Mov Disord,2012

4. An Item Response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies;Evans;J Psychiatr Res,2004

5. Ho AK , Gilbert AS , Mason SL , Goodman AO , Barker RA . Health-related quality of life in Huntington’s disease: Which factors matter most? Mov Disord 2009;24(4):574–8.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol;BMJ Open;2024-08

2. Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov;Clinical Pharmacology & Therapeutics;2024-06-11

3. Influence of anosognosia on patient-reported outcomes for psychiatric symptoms and quality of life in Huntington's disease;Parkinsonism & Related Disorders;2024-06

4. Identifying temporal patterns in the progression of neurodegenerative disease using unsupervised clustering;2024-02-27

5. Detection of illicit phrasal movement in Huntington’s disease;Language, Cognition and Neuroscience;2023-12-15